Aticaprant

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

SchizophreniaMajor Depressive Disorder

174 competitors in Schizophrenia

#DrugCompanyPhaseTrials

1

Aticaprant

Johnson & Johnson

Phase 3

12

Ozempic

Novo Nordisk

Preclinical

13

Resotran

Takeda

Preclinical

14

Inapsine

Jazz Pharmaceuticals

Preclinical

15

Depakote

AbbVie

Preclinical

—6

Ibrance

Pfizer

Preclinical

—7

Lunesta

Akero Therapeutics

Preclinical

38

Luvox

SSolvay Pharmaceuticals

Preclinical

19

Catapres

Boehringer Ingelheim

Preclinical

110

Rapamune

PPrism Pharmaceuticals

Preclinical

1Show 31 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Major Depressive Disorder4 trials

A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure

Terminated·Johnson & Johnson·Phase 3·NCT06635135·47 enrolled

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

Terminated·Johnson & Johnson·Phase 3·NCT06514742·101 enrolled

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)

Active, not recruiting·Johnson & Johnson·Phase 3·NCT05518149·840 enrolled

Show 1 more trial

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

Completed·Johnson & Johnson·Phase 3·NCT05455684·513 enrolled

Anhedonia1 trial

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

Completed·Johnson & Johnson·Phase 3·NCT05550532·444 enrolled

Adult1 trial

A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants

Completed·Johnson & Johnson·Phase 1·NCT05387759·60 enrolled

Schizophrenia1 trial

A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Phase 1b Study to Investigate the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

Recruiting·Johnson & Johnson·Phase 1·NCT07615426·64 enrolled

Details

Drug Info

Related News